Yoo George H, Subramanian Geetha, Piechocki Marie P, Ensley John F, Kucuk Omer, Tulunay Ozlem E, Lonardo Fulvio, Kim Harold, Won Joshua, Stevens Timothy, Lin Ho-Sheng
Department of Otolaryngology-Head and Neck Surgery, Wayne State University, 5E University Health Center, 4201 St Antoine, Detroit, MI 48201, USA.
Arch Otolaryngol Head Neck Surg. 2008 Jul;134(7):735-42. doi: 10.1001/archotol.134.7.735.
To identify the antitumor activity and wound-healing effect of docetaxel delivered in the surgical tumor microenvironment of head and neck squamous cell carcinoma (HNSCC).
Control and experimental series.
Academic medical center.
BALB/c and severe combined immunodeficiency mice.
Intrawound (IW) docetaxel therapy was tested in 3 HNSCC xenograft and 2 taxane-resistant models. Intratumoral (IT) docetaxel therapy was further tested in the 2 taxane-resistant models.
Tumor size, survival, and wound toxic effects were measured. The effect of docetaxel on various factors involved in wound healing and tumor growth within the surgical tumor microenvironment was also analyzed.
In a pilot study using BALB/c mice, IW docetaxel therapy was not associated with problems in wound healing. Using the HN6, HN12, and HN30 HNSCC xenograft model, IW docetaxel prevented tumor growth and improved survival when compared with controls. No local or systemic toxic effect or wound-healing problem was noted. Using taxane-resistant xenograft lung cancer (H460/T800) and syngeneic salivary cancer (BALB/c mucoepidermoid carcinoma) models, IW therapy did not delay tumor growth. An antitumor effect was detected with repeated docetaxel injections in the H460/T800 taxane-resistant model but not in the BALB/c mucoepidermoid carcinoma model. Docetaxel inhibited the expression of growth factors and receptors in tumor cells; however, it did not inhibit the level of wound-healing growth factors in the surgical tumor microenvironment.
These preclinical results support further testing of IW docetaxel treatment in HNSCC. Docetaxel appears to exert antitumor activity without affecting factors involved in wound healing in the tumor microenvironment.
确定多西他赛在头颈部鳞状细胞癌(HNSCC)手术肿瘤微环境中的抗肿瘤活性和伤口愈合作用。
对照和实验系列。
学术医疗中心。
BALB/c和严重联合免疫缺陷小鼠。
在3种HNSCC异种移植模型和2种紫杉烷耐药模型中测试伤口内(IW)多西他赛治疗。在2种紫杉烷耐药模型中进一步测试瘤内(IT)多西他赛治疗。
测量肿瘤大小、生存率和伤口毒性作用。还分析了多西他赛对手术肿瘤微环境中参与伤口愈合和肿瘤生长的各种因素的影响。
在一项使用BALB/c小鼠的初步研究中,IW多西他赛治疗与伤口愈合问题无关。使用HN6、HN12和HN30 HNSCC异种移植模型时,与对照组相比,IW多西他赛可预防肿瘤生长并提高生存率。未观察到局部或全身毒性作用或伤口愈合问题。使用紫杉烷耐药的异种移植肺癌(H460/T800)和同基因唾液腺癌(BALB/c黏液表皮样癌)模型时,IW治疗未延迟肿瘤生长。在H460/T800紫杉烷耐药模型中,重复注射多西他赛可检测到抗肿瘤作用,但在BALB/c黏液表皮样癌模型中未检测到。多西他赛抑制肿瘤细胞中生长因子和受体的表达;然而,它并未抑制手术肿瘤微环境中伤口愈合生长因子的水平。
这些临床前结果支持对HNSCC进行IW多西他赛治疗的进一步测试。多西他赛似乎在不影响肿瘤微环境中伤口愈合相关因素的情况下发挥抗肿瘤活性。